Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2018

Primary Completion Date

January 10, 2024

Study Completion Date

September 30, 2024

Conditions

AmantadineConsciousness DisordersElectroencephalography

Interventions

DRUG

Amantadine Sulfate

intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)

Trial Locations (1)

Hospital of Vipiteno, Sterzing

All Listed Sponsors

lead

Azienda Sanitaria dell'Alto Adige

OTHER

NCT06443827 - Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness | Biotech Hunter | Biotech Hunter